HomeNewsBusinessPress ReleaseLupin signs agreement with Farmanguinhos, Brazil
Trending Topics
Sensex Live
Tenneco Clean Air India IPO Allotment Status
Fujiyama Power Systems IPO GMP
Capillary Technologies IPO
Gold Price

Lupin signs agreement with Farmanguinhos, Brazil

Lupin Ltd. announced today that it has entered into an agreement with Farmanguinhos, Brazil’s largest PSU in Health Care and the Department of Health, Government of Brazil, for the supply of its 4 in 1 combination drug (Rifampicin + Isoniazide + Ethambutol + Pyrazinamide) for tuberculosis.

January 06, 2011 / 19:32 IST
Story continues below Advertisement
Remove Ad

Pharma Major, Lupin Ltd. announced today that it has entered into an agreement with Farmanguinhos, Brazil

first published: Jan 6, 2011 07:28 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Follow Us On: Facebook twitter instagram linkedin telegram youtube
News
Business New Market New Stocks Income Tax Calculator Election Schedule 2024 India News Economy Mutual Funds Personal Finance IPO News Startups New USA Elections New
Features
Gold Rate Today Silver Rate Today Trending News Startups New National News MC Videos MC You Tube
Tools
SIP Calculator 2 SIP Calculator 3 SIP Calculator 1 New SIP Calculator 4
Specials
PowerYourTrade Master Your Money Game Changers
Network 18 Sites
News18 Firstpost CNN News18 CNBC TV18 Forbes History TV18
Personal Finance
Home Loans up to 50 Lakhs Credit Cards Lifetime Free Finance Tracker Fixed Deposits Fixed Deposit Comparison Fixed Income Account Aggregator
Quick Links
About Us New Contact Us Advisory Alert New Advertise with Us New Disclaimer Privacy Policy Cookie Policy Terms & Conditions Careers Financial Terms (Glossary) Analytical & Information Tool New
Download MC Apps:

Copyright © Network18 Media & Investments Limited. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.